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Introduction: Malignant pleural mesothelioma (MPM) is an aggres-
sive, currently incurable tumor with increasing incidence in indus-
trialized countries. Tumor necrosis factor-related, apoptosis-inducing 
ligand (TRAIL) is a member of the TNF family, which induces cancer 
cell death through extrinsic apoptotic pathway, while sparing normal 
cells. The aim of this study was to investigate the antitumor activity 
of recombinant human Apo2L/TRAIL (dulanermin) in combination 
with chemotherapy in MPM in vitro and in vivo.
Methods: In the present studies, we employed a panel of MPM cell 
lines to test the antitumor activity of recombinant human Apo2L/
TRAIL (T) in combination with carboplatin and pemetrexed (CP) in 
vitro and SCID mice.
Results: Results demonstrated a significant increase of apoptosis in 
cell lines treated with CPT compared with those receiving CP or T as 
single agents. This synergistic effect was dependent on the ability of 
CP to increase the expression of the TRAIL receptors DR4 and DR5 
in a p53 manner. The CPT combination was also effective in block-
ing the growth of MPM cell lines in a SCID mice preclinical model.
Conclusions: CPT increases MPM cell death in vitro and in vivo 
compared with CP. In vitro results suggest that chemotherapy sen-
sitizes MPM to TRAIL-dependent apoptosis through p53 activation 
and subsequent upregulation of DRs.
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(J Thorac Oncol. 2014;9: 1008–1017)
Incidence of malignant pleural mesothelioma (MPM) is steadily increasing in industrialized countries because of 
prolonged widespread exposure to asbestos, which represents 
the main etiological factor of this cancer.1,2
Surgery is feasible only in selected cases and current 
standard procedure chemotherapy in unresectable disease is a 
platinum-based doublet with an antifolate agent (pemetrexed 
or raltitrexed), which shows a median overall and progression-
free survival of approximately 12 and 6 months, respectively, 
and a response rate of 20–40%.3,4 Carboplatin is considered 
a valid option in the systemic treatment of advanced MPM 
showing similar activity and a better toxicity profile compared 
with cisplatin.5–7
High refractoriety to systemic treatment, rare, and 
short-term complete responses make MPM a therapeutic chal-
lenge. Improved knowledge about molecular pathways lead 
to several clinical trials investigating biological agents in the 
treatment of MPM, even though they have not found a precise 
placement in the therapeutic strategy yet.
Tumor necrosis factor (TNF)-related, apoptosis-induc-
ing ligand (TRAIL) belongs to the TNF family of death 
ligands inducing the extrinsic apoptotic pathway. Two surface 
death receptors (TRAIL-R1 or DR4 and TRAIL-R2 or DR5), 
two decoy nonfunctional receptors (TRAIL-R3 or DcR1 and 
TRAIL-R4 or DcR2), and the soluble decoy receptor osteo-
protegerin were described.8–13 After the binding of TRAIL to 
DR4/5 and the oligomerization of death receptors, the death-
inducing signaling complex is formed, which includes also the 
Fas-associated death domain (FADD).
FADD recruits and initiates procaspase 8 to active cas-
pase 8, which in turn cleaves and activates the effector caspases 
3, 6, and 7. The subsequent death program is successfully exe-
cuted in “type I” cells, whereas “type II” cells need the activa-
tion of the intrinsic apoptotic pathway,14 through activation of 
the BH3-only protein, Bid, which moves to the mithocondria 
where contributes to Bax and Bak activation. The resulting 
mithocondrial pore formation leads to cytochrome c release 
into the cytosol with the final caspase9 activation.
TRAIL has been identified as a promising antican-
cer agent thanks to its property of killing cancer cells while 
sparing normal cells,15,16 even though both sensitivity and 
resistance mechanisms to TRAIL-induced cell death are not 
completely clarified.17
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Monoclonal agonist antibodies directed against the DR4 
and DR5 (mapatumumab, lexatumumab, apomab, AMG655, 
LBY135) and recombinant human Apo2L/TRAIL (rhApo2L/
TRAIL, dulanermin) have been studied at a preclinical and 
clinical level both as single agents and in combination with 
chemotherapy.18–23
Conflicting evidences about MPM resistance rather 
than sensitivity to TRAIL-induced apoptosis were previously 
reported.20,24 A Swiss group showed that mapatumumab (anti-
DR4) and lexatumumab (anti-DR5) sensitize MPM cell lines 
to the cytotoxic effects of cisplatin and that cell death occurred 
through a synergistic cooperation of the two agents (mapa-
tumumab or lexatumumab plus cisplatin) probably through 
reactive oxygen species (ROS) induction.20
The aim of our study is to investigate for the first 
time the anticancer effects of rhApo2L/TRAIL dulanermin 
(Amgen, Genentech) in combination with the antifolate-based 
doublet chemotherapy employing epithelioid and sarcomatoid 
MPM cell lines and an in vivo preclinical model.
Even though TRAIL-induced apoptosis is believed to be 
p53-independent, several and complex interactions between 
the two pathways were reported suggesting that targeting p53 
might be a promising strategy to sensitize tumors with wild-
type p53 (e.g., MPM) to TRAIL-dependent cell death.25,26 
Thus, we finally investigated whether the improved cytotox-
icity after the combination of rhApo2L/TRAIL plus chemo-
therapy was p53 dependent.
MATERIALS AND METHODS
Cell Lines and Primary Cultures
Peripheral blood mononuclear cells (PBMC) were iso-
lated from peripheral blood of healthy donors using Ficoll-Paque 
PLUS (GE HEALTHCARE, Little Chalfont, Buckinghamshire, 
United Kingdom) according to the manufacturer’s protocol.
We employed three cell lines of epithelioid derivation 
(ZL55, H28, and M14K), three biphasic cell lines (ZL5, SPC111, 
and MSTO-211H), and the sarcomatoid cell line ZL34. PBMC 
and MPM cell lines were maintained in Roswell Park Memorial 
Institute medium (RPMI) 1640 (Gibco-Life Technologies, 
Carlsbad, CA); human foreskin fibroblasts were grown in modi-
fied Dulbecco’s eagle medium (Gibco-Life Technologies); both 
mediums were supplemented with 2 mM L-glutamine, 1 mM 
sodium pyruvate, 10% fetal bovine serum, and 1% (w/v) peni-
cillin/streptomycin (Invitrogen-Life Technologies, Carlsbad, 
CA). All cells were cultured at 37°C in a humidified atmosphere 
containing 5% CO
2
. One MPM primary culture (MPM1801) of 
sarcomatoid mesothelioma was established from fresh human 
pleural mesothelioma surgical specimen. Specimens have 
been obtained from the Thoracic Surgical Unit (University of 
Padua), after patient’s informed consent signature. The project 
was submitted for approval to the Ethical Committee of Istituto 
Oncologico Veneto and to the Ethical Committee for animal 
studies of the University of Padua.
Annexin V Staining
MPM cells were seeded into 12-well plates in 1.0 ml/well 
of complete RPMI 1640 and treated with carboplatin/pemetrexed 
(27 and 42, uM respectively) for 48 hours and/or rhApo2L/TRAIL 
(dulanermin, Amgen Inc., Thousand Oaks, CA; Genentech Inc., 
South San Francisco, CA) 50 ng/ml for 24 hours. In vitro chemo-
therapy concentrations were defined according to the dose induc-
ing the higher cell death in MPM cell lines with the lower cell 
death in normal cells (PBMC and fibroblasts).
Thus, we choose concentration of carboplatin 27 uM 
and pemetrexed 42 uM inducing 10% of apoptosis in ZL55; 
the same concentration of carboplatin induced about 5% 
of apoptosis in ZL34, whereas pemetrexed as single agent 
showed no apoptosis induction with any tested concentration 
(0–100 uM; data not shown). In vitro rhApo2L/TRAIL con-
centrations were defined according to previous data showing 
that these are able to reach similar blood concentrations.27
Time and sequence of exposure to chemotherapy and 
rhApo2L/TRAIL were established according to previous 
data with other TRAIL agonists and considering the phar-
macokinetic of the drugs under study (shorter half-life of 
rhApo2L/TRAIL compared with agonistic antibodies or to 
chemotherapy)20,28 and the doubling times of cell lines (20.89 
hours for ZL55 and 28.12 hours for Zl34, data not shown).
The Annexin V assay was performed using Annexin-
V-Fluos and PI (Roche, Basel, Switzerland) according to 
the manufacturers’ instructions. Cells were collected, centri-
fuged, and then resuspended in 300 uL of Annexin-binding 
buffer, followed by incubation with 1 uL of Annexin V-Fluos 
and 1 uL of PI for 10 minutes at room temperature. Cells 
positive for Annexin V/PI were detected by flow cytometry 
using a FACSCalibur apparatus and CellQuest software (BD 
Biosciences, San Jose, CA), where indicated cells were pre-
treated with the ROS scavenger N-acetyl-cysteine (100 uM) 
overnight. Specific Apoptosis was calculated by the following 
formula: (percentage of Annexin V positive cells in treated 
samples percentage of Annexin V positive cells in untreated 
samples) / (100 percentage of Annexin V positive cells in 
untreated samples) × 100.
Drug interactions were quantified by determining 
the combination index (CI) using the CompuSyn software 
(ComboSyn, Inc., Paramus, NJ), where CI is less than 1, CI is 
equal to 1, and CI is greater than 1 indicated synergistic, addi-
tive, and antagonistic effects, respectively.
Caspases Assay
Caspases assay was performed using fluorometric 
homogenous caspase assay (Roche, Basel, Switzerland). 
MPM cells were seeded into 96-well plates in 0.1 ml/well 
of complete RPMI 1640, treated with carboplatin/peme-
trexed (27 uM and 42 uM respectively) for 48 hours and/or 
rhApo2L/TRAIL (50 ng/ml) for 24 hours, and then incu-
bated with DEVD-Rhodamine 110. Upon cleavage of the 
substrate by activated caspases, fluorescence of the released 
Rhodamine 110 was measured using Victor microplate 
reader (PerkinElmer, Waltham, MA) with an excitation 
wavelength of 480 nM and emission wavelength of 520 nM. 
Specific caspases activity was calculated by the following 
formula: (fluorescence intensity of treated samples fluores-
cence intensity of untreated samples) / (fluorescence inten-
sity of untreated samples).
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Western Blot
Tissue specimens were processed by cryogenic grind-
ing with mortar and pestle to obtain a fine powder. The tissue 
powders and the cell lines were lysed in Mammalian Cells 
Disruption Buffer Paris-Kit (Ambion-Life Technologies, 
Carlsbad, CA) supplemented with phosphatase inhibitor 
cocktail (Roche, Basel, Switzerland) and complete prote-
ase inhibitor cocktail (Roche, Basel, Switzerland). Protein 
concentration was determined by the Coomassie (Bradford) 
Protein Assay Kit (Thermo Scientific, Waltham, MA) using 
bovine serum albumin as standard, and equal amounts of 
proteins were analyzed by SDS-PAGE (12% acrylamide/bis-
acrylamide). Gels were electroblotted onto polyvinylidenedi-
fluoride membranes (Amersham-GE HEALTHCARE, Little 
Chalfont, Buckinghamshire, United Kingdom). In immu-
noblot analysis, membranes were blocked for 1 hour with 
5% nonfat dry milk in tris-buffered saline containing 0.1% 
Tween-20, and incubated at 4°C over night with primary 
antibody direct against p53 (Santa Cruz Biotechnology, 
Dallas, TX), and anti-β-actin antibody (Sigma) used as load-
ing control, followed by horseradish peroxidase-conjugated 
secondary antibodies (Santa Cruz Biotechnology). Finally, 
the membranes were incubated with chemiluminescence 
reagents (Supersignal Pico; Pierce-Thermo Scientific, 
Waltham, MA) and revealed using Chemidoc XRS System 
(Biorad, Hercules, CA).
Flow Cytometry Analysis
Surface expression of TRAIL receptors was evaluated 
by indirect immunostaining using the primary antibodies DR4, 
DR5, DcR1, and DcR2 (Alexis Biochemicals, San Diego, CA) 
followed by Alexa Fluor Goat antimouse immunoglobulin G 
(IgG H+L; Life Technologies, Life Technologies, Carlsbad, 
CA). Nonspecific fluorescence was assessed using normal 
mouse IgG followed by secondary antibody. Flow cytometry 
analysis was performed using a FACSCalibur apparatus and 
CellQuest software (BD Biosciences).Relative expression of 
TRAIL-R was calculated by the following formula: percent-
age of positive cells x mean fluorescence intensity.
Transfections
The siRNA pool (25 nM) for p53 (RIBOXX-Life 
Science, Dresden-Radebeul, Germany) and/or the wild-type 
p53 expression vector (200 ng) were transiently transfected in 
MPM cell lines using LIPOFECTAMINE 2000 (Invitrogen-
Life Technologies, Carlsbad, CA), according to the manu-
facturers’ instructions. The expression levels of p53 were 
evaluated 24 hours after transfection by western blot analysis.
In Vivo Experiments
In vivo experiments were performed in accordance with 
the Padua University Ethic Committee for Animal Testing. Sixty 
SCID male mice at the 6th week were implanted subcutaneously 
(sc) in the right flank with 2 × 106 ZL55 (30 mice) or ZL34 cell 
lines (30 mice) suspended in 0.1 ml volume of RPMI. When tumor 
volume reached 50 mm3, mice were randomized in four groups 
(N = 6 mice/group) and treated by intraperitoneal injection: 
not treated (vehicle 100 uL on day 1); carboplatin/pemetrexed 
(CP, 75 and 100 mg/kg respectively on day 1); rhApo2L/TRAIL 
(T, 60 mg/kg on days 1, 2, and 3); and carboplatin/pemetrexed/
rhApo2LTRAIL (CPT: C 75 mg/Kg and P 100 mg/Kg on day 
1; T: 60 mg/kg on days 1,2,3). rhApo2L/TRAIL schedule and 
dose were established according to previous studies (data on file, 
Amgen Inc., Thousand Oaks, CA/Genentech Inc., South San 
Francisco, CA, 2009).
Tumor volumes were measured with a caliper every 
third day; volumes were calculated using the modified ellip-
soidal formula: 1/2 (length × width).2 Mice were suppressed 
at the 21th day or when tumor volume reached 500 mm3. Delta 
volume was calculated by the following formula: (tumor vol-
ume at the day n tumor volume at the day 1) / tumor volume 
at the day 1 × 100.
Statistical Analysis
All data were analyzed using the SigmaPlot software, 
and results were expressed as means ± standard errors for in 
vitro experiments and means ± standard deviation for in vivo 
experiments. To compare different groups of treatment, we 
use the Mann-Whitney test for in vitro studies and the analysis 
of variance followed by least significant difference post hoc 
test for in vivo studies. Difference was considered significant 
with a p value ≤ 0.05.
RESULTS
rhApo2L/TRAIL Triggers Apoptosis in 
MPM Cells But Not in Normal Cells
The induction of apoptosis by rhApo2L/TRAIL treatment 
was tested in seven MPM cell lines (three epithelioid: ZL55, 
H28, and M14K; one sarcomatoid: ZL34; and three biphasic: 
MSTO-211, SPC111, and ZL5) and one short-term primary 
culture of sarcomatoid MPM cells established from a patient 
(MPM1801). Cells were treated with 50 ng/ml rhApo2L/TRAIL 
for 24 hours and apoptosis was measured by Annexin V stain-
ing and fluorometric homogenous caspase assays. The results 
showed a significant, although heterogeneous, sensitivity of 
MPM cells to TRAIL treatment, independent from the histo-
type. Interestingly, this effect was specific for MPM cells, as 
significant death was not observed in control cells (human 
foreskin fibroblasts and PBMC; Fig. 1 and Supplementary 
Figure 1A, SDC 1, http://links.lww.com/JTO/A594).
Carboplatin and Pemetrexed Enhance the 
Proapoptotic Effects of rhAPo2L/TRAIL  
on MPM Cell Lines
As carboplatin and pemetrexed(CP) are the corner-
stone of current MPM therapies, we next tested whether 
these drugs might synergize with rhApo2L/TRAIL (T). 
Apoptosis was measured by Annexin V staining and flow 
cytometry. Cell lines ZL34 and ZL55 were selected as repre-
sentative of sarcomatoid and epitheliod MPM, respectively. 
Results showed a significant (p < 0.001) synergistic effect 
of the combination of these drugs compared with no treat-
ment or with CP or T as single agents (Fig. 2; Supplementary 
Figure 1C, SDC 1, http://links.lww.com/JTO/A594). These 
results were also confirmed when apoptosis was assessed 
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FIGURE 1.  Anticancer effects of rhAPO2L/tumor 
necrosis factor-related, apoptosis-inducing ligand 
(TRAIL) in malignant pleural mesothelioma (MPM) 
cell lines and primary culture. MPM cell lines 
and control cells (human foreskin fibroblasts and 
peripheral blood mononuclear cells) were treated 
with rhAPO2L/TRAIL (T) 50 ng/ml for 24 hours and 
Annexin V staining was evaluated. Results were 
represented as mean ± SE of three different experi-
ments running in duplicate. *Statistically significant 
difference of specific apoptosis between MPM 
cells treated with rhAPO2L/TRAIL compared with 
untreated cells (p < 0.05) by Mann-Whitney test.
FIGURE 2.  Chemotherapy sensitizes 
MPM cell lines to rhAPO2L/ tumor 
necrosis factor-related, apoptosis-
inducing ligand (TRAIL) induced cell 
death. ZL55 and ZL34 cell lines were 
previously treated with carboplatin 
plus pemetrexed (CP) for 24 hours 
followed by rhAPO2L/TRAIL (T) 
50 ng/ml for 24 hours and apoptosis 
induction was evaluated by Annexin 
V/PI staining. A representative dot 
blot is shown (upper panel); NT, not 
treated control. Mean of specific 
apoptosis ± SE of three independent 
experiments running in triplicate 
are given (lower panel). *Statistically 
significant difference of specific 
apoptosis between malignant pleural 
mesothelioma (MPM) cells treated 
with CPT compared with MPM 
cells treated with CP (p < 0.001) by 
Mann-Whitney test.
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with the caspases assay (Supplementary Figure 1B, SDC 1, 
http://links.lww.com/JTO/A594). A similar effect was shown 
in all the cell lines tested (three epithelioid, three biphasic 
and one sarcomatoid) and in the sarcomatoid primary cul-
ture (Supplementary Figure 2A; SDC 2, http://links.lww.
com/JTO/A595).
Previous studies20 suggested that sensitivity to TRAIL 
might be dependent on the levels of ROS. However, we did 
not observe any difference in specific cell death when both 
ZL34 and ZL55 cell lines were treated with the ROS scaven-
ger N-acetyl-cysteine (Supplementary Figure 2, SDC 2, http://
links.lww.com/JTO/A595).
p53 Activation by Carboplatin and  
Pemetrexed Sensitizes to TRAIL-Dependent  
Apoptosis In Vitro
We next investigated the mechanisms at the basis of the 
sensitization to TRAIL-dependent apoptosis induced by CP. 
Considering that both carboplatin and pemetrexed induced 
DNA damage resulting in p53 activation and that p53 is not 
mutated in most MPM cases,45 we tested the effect of CP on 
p53 levels in the ZL55 and ZL34 cell lines. Results indicated 
an increase in p53 levels in ZL55 and ZL34 cell lines after 
CP treatment (Fig. 3A). To test whether this increase in p53 
levels accounts for the ability of CP to sensitize to TRAIL-
induced apoptosis, we investigated cell death in ZL55 and 
ZL34 cell lines treated with CP and/or T after p53 knock down 
by siRNAs. Results demonstrated that the siRNA treatment 
induced a significant, specific knock down of p53 expression 
(Fig. 3A; Supplementary Figure 2C, SDC 2, http://links.lww.
com/JTO/A595). Interestingly, p53 silencing resulted in a sig-
nificant reduction of cell death induced by CP and T (Fig. 3B); 
importantly, this effect was reverted by cotransfection with a 
vector coding for wild-type p53 (Fig. 3B). We observed no or 
weak p53 expression in five tumor tissues from MPM patients; 
in contrast, p53 was readily detected in the ZL34 and ZL55 
cell lines after p53 vector (Supplementary Figure 2C, SDC 2, 
http://links.lww.com/JTO/A595).
FIGURE 3.  p53 activation by chemotherapy sensitizes MPM cell lines to rhAPO2L/tumor necrosis factor-related, apoptosis-induc-
ing ligand-dependent cell death. A, western blot analysis of p53 protein expression levels in ZL55 and ZL34 cell lines treated or not 
with CP for 24 hours. Where indicated, cells were previously treated with 25 nM of negative control scrambled sequence (scrbl) or 
siRNA-p53. (B) malignant pleural mesothelioma (MPM) cell lines were treated with scrbl or siRNA-p53 (25 nM) in presence or not 
of wild-type p53 vector (200 ng) for 24 hours followed by CP and/or T stimulation and Annexin V/PI assay was performed. Results 
were represented as mean ± SE of three different experiments running in duplicate. *Statistically significant difference of specific 
apoptosis between MPM cells treated with scrbl plus CPT compared with cells treated with siRNA-p53 plus CPT (p < 0.05) by 
Mann-Whitney test. C. A representative dot blot of cells treated with scrbl plus CPT versus siRNA-p53 plus CPT is shown.
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p53 Activation Increases the Expression 
of TRAIL Receptors In Vitro
To explore the TRAIL-sensitizing effect of p53 activa-
tion, we next investigated whether p53-inducing treatments 
enhance the expression of the TRAIL receptors DR4/DR5 and 
DcR1/DcR2. Results showed that the ZL55 and ZL34 cell lines 
expressed higher levels of DR4 and DR5 in response to CP treat-
ment (Fig. 4A,B). Interestingly, knock down of p53 expression 
resulted in a significant reduction of CP-induced DR4 and DR5 
expression in MPM cells (p < 0.05), whereas no reduction of 
DR4 and DR5 expression was observed in MPM cells cotrans-
fected with the p53siRNAplus wild-type p53 expression vec-
tor (Fig. 5A,B). Taken together, these data provide evidence of 
a causal link between CP treatment, p53 activation, increased 
expression of DR4 and DR5 receptors, and sensitivity to TRAIL. 
The detection of DcR1 and DcR2 levels in ZL34 and ZL55 cell 
lines treated or not with CP seemed not relevant (Fig. 4A).
Antitumor Activity of Apo2L/TRAIL 
in a Preclinical Model of MPM
To test the in vivo efficacy of Apo2L/TRAIL as single 
agent and in combination with CP, we employed a preclinical 
model based on the subcutaneous injection of the ZL55 and 
ZL34 MPM cell lines in SCID mice.
Thirty SCID mice were inoculated with ZL55 and 30 
SCID mice were inoculated with ZL34 cells. Twenty-four 
mice had a measurable tumor and were randomized in the four 
treatment groups (N = 6/group). Mice inoculated with ZL55 
cells showed a statistically significant reduction of tumor vol-
ume at every time point in the three treatment groups (CP, T, 
and CPT) compared with not treated mice; moreover, tumor 
volume was significantly reduced in mice treated with CPT 
compared with CP at the 21th day (p < 0.05; Fig. 6A).
Mice inoculated with ZL34 cells showed a statistically 
significant reduction of tumor volume at every time point 
FIGURE 4.  Chemotherapy increases DR4 and DR5 tumor necrosis factor-related, apoptosis-inducing ligand (TRAIL) receptors 
in malignant pleural mesothelioma (MPM) cell lines. Flow cytometry analysis of TRAIL receptors expression levels in ZL55 and 
ZL34 cell lines treated with carboplatin/pemetrexed (CP) for 24 hours. A. Representative dot blot. P ≤ 0.001 indicate differences 
in fluorescence between cells untreated compared with cells treated with CP by Kolmogorov-Smirnov Statistics. (B) The graph 
bar represents the mean of relative expression of TRAIL-R (for DR4 and DR5) ± SE of three independent experiments running 
in triplicate. *Statistically significant difference of receptor expression levels between MPM cells untreated (NT) compared with 
MPM cells treated with CP (p < 0.05) by Mann-Whitney test.
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in T and CPT treatment groups compared with not treated; 
at the day 21, we observed a statistically significant differ-
ence of tumor volume between all three treatment groups and 
untreated mice and between CPT and CP groups (Fig. 6B). No 
significant difference was observed between mice treated with 
CP compared with T (Fig. 6A,B).
DISCUSSION
Malignant pleural mesothelioma shows high refracto-
riety to chemotherapy and radiotherapy, thus median overall 
survival and progression-free survival are approximately 12 
and 6 months, respectively, in patients not eligible for surgery. 
Since 2003, when antifolate agents were introduced in the 
clinical management of this disease, the standard procedure 
chemotherapy is a platinum-based doublet plus pemetrexed or 
raltitrexed.3,4 Surgery is feasible in highly selected cases, and 
patients suitable for trimodal treatment (neoadjuvant chemo-
therapy, surgery, postoperative radiotherapy) achieve overall 
survival longer than 25 months.29
After the standard first-line pemetrexed/platinum 
combination, there is not a defined regimen for the second-
line treatment of MPM, and the clinical benefits are uncer-
tain.30–33 Recent studies tested biologic agents that target key 
oncogenic pathways, including phosphatidylinositol3-kinase 
(PI3K)/mammalian target of rapamycin (mTOR) pathways, 
histone deacetylases, nuclear factor kB, and neoangiogenesis. 
However, no one of these therapies proved to significantly 
impact the natural history of this neoplasm, thus reinforc-
ing the need for new drugs to improve prognosis of MPM 
patients. TRAIL is a member of the TNF superfamily which 
has recently emerged as a potentially interesting anticancer 
agent because of its ability to kill cancer cell lines whereas 
sparing many normal cells.15,34,35
However, cancer cells are frequently resistant to 
TRAIL-dependent apoptosis through different mechanisms: 
mutations and disfunction of DR4 and DR5; defects of FADD 
and caspase 8; overexpression of cellular FADD-like interleu-
kin-1b-converting enzyme inhibitory protein (cFLIP); overex-
pression of the antiapoptotic proteins Bcl-2, Bcl-Xl, inhibitor 
of apoptosis proteins; loss of proapoptotic proteins Bax, Bak; 
decreased release of second mithocondria-derived activator of 
caspases (Smac-Diablo); and activation of mitogen-activated 
protein kinases or nuclear factor kB.17
“Type II” cancer cells seem sensitive to the synergistic 
effect of TRAIL, acting on the extrinsic pathway, and DNA dam-
aging agents, targeting the intrinsic pathway; the mechanism 
FIGURE 5.  p53 silencing reduces chemotherapy-induced tumor necrosis factor-related, apoptosis-inducing ligand (TRAIL) 
receptors expression in malignant pleural mesothelioma (MPM) cell lines. Flow cytometry analysis of TRAIL receptors expression 
levels in ZL55 and ZL34 cell lines treated with negative control scrambled sequence (scrbl) or siRNA-p53 (25 nM) in presence 
or not of wild-type p53 vector (200 ng) for 24 hours followed by CP treatment. A, representative dot blot representing MPM 
cells treated with scrbl plus CP versus siRNA-p53 plus CP. p ≤ 0.001 indicate differences in fluorescence by Kolmogorov-Smirnov 
Statistics. (B) The results were represented as mean of relative expression of TRAIL-R ± SE of three different experiments run-
ning in duplicate. *Statistically significant difference of receptor expression levels between MPM cells treated with scrbl plus CP 
compared with MPM cells treated with siRNA-p53 plus CP (p < 0.05) by Mann-Whitney test.
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of this synergy has been proposed to be through the upregula-
tion of the TRAIL receptor DR5.36–38 Several studies showed 
that MPM cells are resistant to TRAIL in vitro, although this 
resistance can be overcome by combining chemotherapy with 
alpha-tocopherylsuccinate, anisomycin, histone deacetylases 
inhibitors, proteasome inhibitors, and FLICE-like inhibitory 
protein (FLIP) siRNA.20,39–44
Increased apoptotic levels were demonstrated in four cell 
lines treated with the association of TRAIL and chemotherapy 
(cisplatin, doxorubicin, gemcitabine, or etoposide), probably 
through p53-independent apoptotic pathway; no DR5 increase 
was observed at the basis of this sensitization.42 Recently, another 
study showed apoptotic effects of TRAIL or the monoclonal 
antibodies mapatumumab and lexatumumab directed against 
DR4 and DR5 on 13 MPM cell lines; this effect was enhanced 
by cisplatin probably through the induction of ROS.20
Other studies showed a p53-dependent induction of DR4 
and DR5 expression by Alpha-tocopheryl succinate, resulting 
in TRAIL sensitization.43 Although TRAIL-dependent apop-
tosis is thought to be p53-independent, p53 wild-type cancer 
cells can be sensitized to TRAIL through p53 activation.26 In 
contrast to most solid tumors, MPM cells frequently express 
wild-type p53.45
Recombinant human (rh) Apo2L/TRAIL (dulanermin), 
a receptor agonist which binds both DR4 and DR5,28,46 showed 
antitumor activity in vitro and in vivo tumor models of dif-
ferent cancer types both as single agent and in combination 
with chemotherapy without any toxicity in normal cells35,47,48 
and was the first TRAIL agonist investigated in human clinical 
trials.22,23,49
In the present study, we investigated proapoptotic effects 
of rhApo2L/TRAIL combined to carboplatin and pemetrexed. 
To our knowledge, this is the first in vivo study of a TRAIL 
agonist in mesothelioma. We observed heterogeneous sensi-
tivity of seven mesothelioma cell lines and one primary cul-
ture to rhApo2L/TRAIL treatment; higher or lower sensitivity 
to the TRAIL agonist did not seem to be dependent on the his-
tologic subtype (Fig. 1). These data seem in line with previous 
studies of TRAIL agonists in vitro and might be explained by 
the variable expression levels of antiapoptotic proteins such 
as Bcl-2 and inhibitor of apoptosis proteins-family proteins, 
or other proteins involved in the apoptotic pathway.20 These 
proteins have been previously suggested as useful predictive 
markers of sensitivity to TRAIL-dependent apoptosis.
We observed higher apoptotic levels when both epithelioid 
and sarcomatoid cell lines were treated with chemotherapy and 
rhApo2L/TRAIL compared with carboplatin/pemetrexed and 
rhApo2L/TRAIL alone (Fig. 2). This effect seemed to be depen-
dent upon p53 but not on increased ROS levels (Supplementary 
Figure 2, SDC 2, http://links.lww.com/JTO/A595 and Fig. 3). 
Furthermore, we showed that p53 activation leads to increased 
expression of the DR4 and DR5 receptors (Fig. 4).
Previous evidences showed that chemotherapy-induced 
p53 activation lead to antiapoptotic proteins downregulation 
(such as survivin or Mcl1) and proapoptotic targets upregula-
tion (such as Bax).20,50 Contrary to previous evidences,45 pre-
liminary data from next generation sequencing of 123 MPM 
samples showed that p53 was among the five most frequently 
altered genes.51
Our results in a primary culture of sarcomatoid MPM 
(MPM1801) showed no mutation in p53 gene (data not 
shown). Thus, based on our results, it is tempting to speculate 
that p53 mutational status in MPM samples may be a predic-
tive marker of sensitivity to the combination of chemotherapy 
and rhApo2L/TRAIL. This hypothesis will be thoroughly 
tested in further studies in p53 knock-out models.
In vivo studies showed that the association of carbopla-
tin/pemetrexed with rhApo2L/TRAIL significantly reduced 
tumor growth compared with carboplatin/pemetrexed in both 
cell lines tested (Fig. 6). Considering the short-term responses 
achieved with currently used chemotherapy, especially in 
the neoadjuvant setting where tumor shrinkage and distant 
A
B
FIGURE 6.  In vivo antitumor activity of carboplatin/
pemetrexed plus rhAPO2L/ tumor necrosis factor-related, 
apoptosis-inducing ligand (TRAIL) in malignant pleural meso-
thelioma (MPM). Mice were subcutaneously injected with 
2 × 106 of ZL55 (A) or ZL34 (B) cell lines and randomized in 
four treatment groups (n = 6/group). When tumor volumes 
reached 50 mm3 (day 1), each group received by intraperi-
toneal injection vehicle or carboplatin/pemetrexed (CP; on 
day 1) or rhAPO2L/TRAIL (T; on days 1, 2, and 3) or CPT (on 
day 1 and days 1, 2, and 3 respectively). Tumor volumes 
were recorded every third day. The results were represented 
as mean of delta volume ± standard deviation. *Statistically 
significant difference of delta tumor volume between treated 
groups and untreated controls (p < 0.05). §Statistically signifi-
cant difference of delta tumor volume between CPT and CP 
(p < 0.05) by analysis of variance followed by least significant 
difference post hoc test.
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relapses prevention assume particular relevance, the syner-
gistic effect of chemotherapy combined to rhApo2L/TRAIL 
might improve patients’ prognosis.
Moreover, similar antitumor effects of rhApo2L/TRAIL 
and chemotherapy in vivo might suggest a role for such agent 
at the disease progression after the first-line treatment, where 
a valid option is still lacking in patients eligible for further 
treatments.
Taken together our findings suggest that rhApo2L/
TRAIL combined to standard chemotherapy as first-line treat-
ment and as single agent in the second-line setting might prove 
to be an effective drug in the treatment of MPM, considering 
also its low toxicity profile.
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